Patients with wet AMD demonstrate increased vascular endothelial growth factor (VEGF) within the choroidal vasculature, prompting neovascularization; therefore, treatment for wet AMD is centered on anti-VEGF drugs, including brolucizumab, ranibizumab, and KSI-301 [9–12]. This evidence concerns the gene VEGFA and wet macular degeneration.